ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act By Ogkologos - June 11, 2025 620 0 Facebook Twitter Google+ Pinterest WhatsApp Ensuring equitable access to cancer treatments remains central to EU health security efforts Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Young Adult Cancer Awareness Week: Recognizing Adolescent and Young Adults Cancer... April 5, 2021 Growing the Cancer Research Pipeline by Expanding Opportunities August 29, 2024 No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... March 24, 2025 Inspiring the next generation of cancer researchers November 16, 2021 Load more HOT NEWS Long-Term Outcomes in Patients with Metastatic Melanoma Treated with Anti-PD1 Therapy... Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC
